[PDF][PDF] Targeting HIF2α in clear-cell renal cell carcinoma
CJ Ricketts, DR Crooks, WM Linehan - Cancer cell, 2016 - cell.com
CJ Ricketts, DR Crooks, WM Linehan
Cancer cell, 2016•cell.comIn two recent studies, the HIF2α antagonist, PT2399, decreased HIF2α-dependent
transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma
(ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal
variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-
driven clinical trials.
transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma
(ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal
variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-
driven clinical trials.
In two recent studies, the HIF2α antagonist, PT2399, decreased HIF2α-dependent transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials.
cell.com